Aging and Hematology

The SWG "Aging and Hematology" has four main goals for the next four years (2019-2023):

To share clinically useful tools in assessing frailty and comorbidities in older adults with hematologic malignancies.

Recommendations for COVID-19

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Long-lasting, late-onset, and chronic idiopathic neutropenia project, February 2025 update

A project update from Dr Grigorios Tsaknakis.

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

This press release is originally found here: http://prn. to/2YF7Js3

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI).

Without access to treatment, can we truly innovate in rare diseases?

Interview with Giampaolo Merlini

There have been many developments on rare diseases since the EU Orphan Medicinal Products Regulation came into force in 2000. As the European Commission is evaluating its effectiveness, EHA discussed with Prof.

EHA leads Tutorial in Kazakhstan for better understanding of lymphomas

EHA, in collaboration with the Kazakhstan Cancer Society (KCS) and Kazakh Institute of Oncology and Radiology (KazIOR), organized its very first tutorial together on March 14-16 in Almaty, Kazakhstan.

Registration

Registration is now closed.

Red Cells and Iron

This SWG covers the clinical areas of inherited and acquired disorders of the erythrocyte and iron metabolism.